Search Results for "arterial"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for arterial. Results 41 to 44 of 44 total matches.
Drugs for Chronic Heart Failure
The Medical Letter on Drugs and Therapeutics • May 26, 2025 (Issue 1729)
or have a serum creatinine level >3 mg/dL,
a serum potassium level >5.0 mEq/L, or bilateral renal
artery ...
Pharmacologic management of chronic heart failure
(HF) is primarily determined by the patient's left
ventricular ejection fraction (LVEF) and severity of
symptoms. Patients with chronic HF who have an
LVEF ≤40% are considered to have heart failure with
reduced ejection fraction (HFrEF) and those with an
LVEF ≥50% are considered to have heart failure with
preserved ejection fraction (HFpEF). Patients with an
LVEF of 41-49% have heart failure with mildly reduced
or mid-range ejection fraction.
Med Lett Drugs Ther. 2025 May 26;67(1729):81-8 doi:10.58347/tml.2025.1729a | Show Introduction Hide Introduction
Drugs for Treatment and Prevention of Venous Thromboembolism
The Medical Letter on Drugs and Therapeutics • Jul 25, 2022 (Issue 1655)
coronary events, is not
recommended for treatment of VTE in patients with
coronary artery disease.27
INR ...
Anticoagulants are the drugs of choice for treatment
and prevention of deep venous thrombosis (DVT) and
pulmonary embolism (PE), collectively referred to as
venous thromboembolism (VTE). US guidelines for
treatment of VTE were updated in 2020 and 2021.
Drugs for COPD
The Medical Letter on Drugs and Therapeutics • Sep 02, 2024 (Issue 1710)
only in those with severe dyspnea; there was no
significant difference between the groups in arterial ...
The main goals of treatment of chronic obstructive
pulmonary disease (COPD) are to relieve symptoms,
reduce the frequency and severity of exacerbations,
prevent disease progression, and reduce mortality.
GOLD (Global Initiative for Chronic Obstructive Lung
Disease) guidelines for treatment of COPD were
updated recently. Treatment of acute exacerbations
is not discussed here. Drugs available for treatment
of COPD are listed in Tables 1 and 3.
Med Lett Drugs Ther. 2024 Sep 2;66(1710):137-44 doi:10.58347/tml.2024.1710a | Show Introduction Hide Introduction
Comparison Chart: Some Drugs for HFrEF
The Medical Letter on Drugs and Therapeutics • May 26, 2025 (Issue 1729)
creatinine level >3 mg/dL, serum potassium >5.0 mEq/L, or bilateral renal artery stenosis
. Should ...
View the Comparison Chart: Some Drugs for HFrEF
Med Lett Drugs Ther. 2025 May 26;67(1729):e1-15 doi:10.58347/tml.2025.1729b | Show Introduction Hide Introduction